Mazdutide
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent · Phase 1/2 · Active, not recruiting · Enrollment 98
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| IBI362 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.